Exelixis, Inc. — Form 10-Q Summary
Period clarification: The request metadata says 2015 Q1, but the supplied filing is Exelixis’s first-quarter 2016 Form 10-Q. It covers the quarter ended April 1, 2016 (financial statements presented as March 31, 2016), with comparisons to the three months ended March 31, 2015.
Business context and reporting period
Exelixis is a biopharmaceutical company focused primarily on developing and commercializing cabozantinib. At quarter-end, COMETRIQ was marketed for medullary thyroid cancer; CABOMETYX was approved for advanced renal cell carcinoma on April 25, 2016, after the reporting period. The company also shares U.S. profits and losses and receives ex-U.S. royalties from Genentech’s COTELLIC collaboration.
Financial performance and position
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Total revenue | $15.4 million | $9.4 million |
| Net product revenue | $9.1 million | $9.4 million |
| License and contract revenue | $6.3 million | None reported |
| Gross margin | 92% | 92% |
| Research and development expense | $28.9 million | $22.3 million |
| Selling, general and administrative expense | $34.9 million | $9.5 million |
| Operating loss | $49.1 million | $22.8 million |
| Net loss | $61.3 million | $35.2 million |
| Net loss per share | $0.27 | $0.18 |
| Operating cash flow | $154.9 million provided | $45.1 million used |
Revenue increased 64%, mainly due to the Ipsen collaboration and a $5.0 million Merck milestone. The $200.0 million Ipsen upfront payment is being recognized over the agreement term; $1.2 million was recognized as license revenue in the quarter, and $198.8 million remained deferred at quarter-end. Operating cash flow benefited principally from receipt of that upfront payment and does not represent recurring operating earnings.
SG&A rose 266%, primarily reflecting expanded commercial staffing and launch preparation for CABOMETYX, COTELLIC commercialization costs, and stock-based compensation. R&D rose 30%, including higher stock-based compensation, personnel, and outside-service costs.
At March 31, cash and investments totaled $407.6 million. Management identified $323.3 million as available for operations; $81.6 million was required as compensating balances and $2.7 million was long-term restricted. Total debt carrying value was $388.7 million: $203.9 million for the 2019 convertible notes, $104.8 million for Deerfield notes, and an $80.0 million bank term loan. The filing reports a $27.5 million current portion of convertible notes associated with a potential Deerfield prepayment obligation.
Material changes, outlook, and risks
- Ipsen agreement: Ipsen paid $200.0 million upfront for exclusive cabozantinib commercialization rights outside the U.S., Canada, and Japan. Exelixis may also receive development and regulatory milestones, sales-based contingent payments, and tiered royalties; it remains responsible for supply and funds existing-trial development.
- Commercial launch: CABOMETYX was FDA-approved for previously treated advanced RCC on April 25, 2016, and shipped shortly thereafter. The filing cites METEOR trial results supporting the approval, including median overall survival of 21.4 months versus 16.5 months for everolimus. These are post-quarter events.
- Management outlook: The company expected R&D expense to remain approximately flat during 2016, with lower clinical-trial costs offset by medical-affairs costs. It expected SG&A for the remainder of 2016 to be in line with first-quarter results. Management expected available cash, short-term investments, and product revenue to support operations for at least 12 months after the filing date, while cautioning that additional capital might be needed sooner depending on business performance and costs.
- Development: Exelixis expected top-line results from the phase 3 CELESTIAL HCC trial in 2017 and anticipated 2016 results from several earlier-stage cabozantinib studies. It noted that prior phase 3 prostate-cancer trials failed their primary endpoints.
- Collaboration dispute: On May 3, 2016, Exelixis issued Genentech a formal notice of dispute over COTELLIC development, pricing, commercialization, and U.S. cost and revenue allocations. Exelixis said it intended to initiate arbitration if the dispute was not resolved within 30 days of receipt.
- Key risks: CABOMETYX uptake, competition, reimbursement and pricing, clinical and regulatory outcomes, manufacturing and distribution dependence, continued operating losses, significant debt service, and reliance on partners. A potential $27.5 million Deerfield prepayment in January 2017 depended on the noteholders’ election.
Most important facts for investors to verify
- Confirm the filing period: the supplied document is Q1 2016, not Q1 2015.
- Track CABOMETYX launch sales and whether commercial revenue can offset the sharp rise in selling and marketing costs.
- Assess the Genentech dispute’s resolution and its effect on Exelixis’s COTELLIC economics.
- Review cash available for operations separately from required compensating balances, deferred Ipsen revenue, and reported operating cash flow.
- Verify Deerfield prepayment and maturity obligations, the 2017 bank-loan balloon payment, and the 2019 convertible-note maturity.
- Monitor CELESTIAL results, other clinical milestones, and the timing of any European regulatory decision.